Yeah, it's crazy how long the timeline is, particularly when we're talking about drugs that have been around for decades. The good news is the safety profiles have been fabulous. Although the inhalation does appear riskier, so far it hasn't really caused many adverse events for the volunteers. A little bit of a cough when you first start it, but then everyone appears to get used to it. The inhaler is a little complicated and that might be an issue for someone in a bad off state. Certainly not as easy as a sublingual strip. Also, the seal packs for the capsules are a little bulky to carry around.

I think both drugs will get approval, but I have much more confidence long term in Acorda than Cynapsus. Acorda is a well capitalized biotech with a few successful MS drugs already on the market. They have a fabulous management team. Cynapsus is much smaller and everything hinges on this trial for their future.